Why paracetamol (acetaminophen) is a suitable first choice for treating mild to moderate acute pain in adults with liver, kidney or cardiovascular disease, gastrointestinal disorders, asthma, or who are older
Open accessThe DOI matches its Crossref record; 125 of the 125 references it cites were found in a registry or an index.
Abstract
Acute pain is among the most common reasons that people consult primary care physicians, who must weigh benefits versus risks of analgesics use for each patient. Paracetamol (acetaminophen) is a first-choice analgesic for many adults with mild to moderate acute pain, is generally well tolerated at recommended doses (≤4 g/day) in healthy adults and may be preferable to non-steroidal anti-inflammatory drugs that are associated with undesirable gastrointestinal, renal, and cardiovascular effects. Although paracetamol is widely used, many patients and physicians still have questions about its suitability and dosing, especially for older people or adults with underlying comorbidities, for whom there are limited clinical data or evidence-based guidelines. Inappropriate use may increase the risks of both overdosing and inadequate analgesia. To address knowledge deficits and augment existing guidance in salient areas of uncertainty, we have researched, reviewed, and collated published evidence and expert opinion relevant to the acute use of paracetamol by adults with liver, kidney, or cardiovascular diseases, gastrointestinal disorders, asthma, or/and who are older. A concern is hepatotoxicity, but this is rare among adults who use paracetamol as directed, including people with cirrhotic liver disease. Putative epidemiologic associations of paracetamol use with kidney or cardiovascular disease, hypertension, gastrointestinal disorders, and asthma largely reflect confounding biases and are of doubtful relevance to short-term use (<14 days). Paracetamol is a suitable first-line analgesic for mild to moderate acute pain in many adults with liver, kidney or cardiovascular disease, gastrointestinal disorders, asthma, and/or who are older. No evidence supports routine dose reduction for older people. Rather, dosing for adults who are older and/or have decompensated cirrhosis, advanced kidney failure, or analgesic-induced asthma that is known to be cross-sensitive to paracetamol, should be individualized in consultation with their physician, who may recommend a lower effective dose appropriate to the circumstances.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Antman, E. M., Bennett, J. S., Daugherty, A., Furberg, C., Roberts, H., & Taubert, K. A. (2007) · Circulation · doi:10.1161/circulationaha.106.181424 · Cited by 804
Guidance on the management of pain in older people
(2013) · Age and Ageing · doi:10.1093/ageing/afs200 · Cited by 727
Graham, G. G., Davies, M. J., Day, R. O., Mohamudally, A., & Scott, K. F. (2013) · Inflammopharmacology · doi:10.1007/s10787-013-0172-x · Cited by 671
Role of CYP2E1 in the Hepatotoxicity of Acetaminophen
Lee, S. S. T., Buters, J. T. M., Pineau, T., Fernandez-Salguero, P., & Gonzalez, F. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.20.12063 · Cited by 656
Prophylactic aspirin and risk of peptic ulcer bleeding
Weil, J., Colin-Jones, D., Langman, M., Lawson, D., Logan, R., Murphy, M., Rawlins, M., Vessey, M., & Wainwright, P. (1995) · BMJ · doi:10.1136/bmj.310.6983.827 · Cited by 568
Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice
Jenkins, C., Costello, J., & Hodge, L. (2004) · BMJ · doi:10.1136/bmj.328.7437.434 · Cited by 451
Assessment and measurement of pain in older adults
Herr, K. A., & Garand, L. (2001) · Clinics in Geriatric Medicine · doi:10.1016/s0749-0690(05)70080-x · Cited by 417
Paracetamol: not as safe as we thought? A systematic literature review of observational studies
Roberts, E., Delgado Nunes, V., Buckner, S., Latchem, S., Constanti, M., Miller, P., Doherty, M., Zhang, W., Birrell, F., Porcheret, M., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206914 · Cited by 412
Cardiovascular effects and safety of (non-aspirin) NSAIDs
Schjerning, A.-M., McGettigan, P., & Gislason, G. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0366-z · Cited by 387
Nonsteroidal Antiinflammatory Drugs, Acetaminophen, and the Risk of Cardiovascular Events
Chan, A. T., Manson, J. E., Albert, C. M., Chae, C. U., Rexrode, K. M., Curhan, G. C., Rimm, E. B., Willett, W. C., & Fuchs, C. S. (2006) · Circulation · doi:10.1161/circulationaha.105.595793 · Cited by 319
Research works printed but not linked: 7
- Jóźwiak-Bębenista M, 2014, Acta Pol Pharm, 71, 11
- Hunt RH, 2007, Can Fam Physician, 53, 1177
- Pavličević I, 2008, Can J Clin Pharmacol, 15, e372–382
- Wójcicki J, 1984, Pol J Pharmacol Pharm, 36, 59
- Kaas Oldenburg LI, 2020, J Pharm (Cairo), 2020, 1354209
- Bannwarth B, 2001, J Rheumatol, 28, 182
- Foster J, 2016, Front Pharmacol, 7, 54
Cited by
Mallet, C., Desmeules, J., Pegahi, R., & Eschalier, A. (2023) · Journal of Pain Research · doi:10.2147/jpr.s393809 · Cited by 83
“It is unnecessary to modify the dose for dialytic patients; however, dose reduction or longer dose interval should be considered in patients with advanced kidney failure.(6) NSAIDs significantly increase the risk of cardiovascular adverse outcomes.”
BackgroundInfluentialPodder, D., Stala, O., Hirani, R., Karp, A. M., & Etienne, M. (2025) · Neurology International · doi:10.3390/neurolint17060094 · Cited by 55
Subash, R., Madhivanan, K., Atchudan, R., Arya, S. K., & Sundramoorthy, A. K. (2025) · Diamond and Related Materials · doi:10.1016/j.diamond.2024.111940 · Cited by 28
Alirezapour, F., Bamdad, K., Khanmohammadi, A., & Ebrahimi, N. (2022) · Journal of Molecular Modeling · doi:10.1007/s00894-022-05305-6 · Cited by 27
Jasim, M. H. M., & Mustafa, Y. F. (2024) · Chemistry & Biodiversity · doi:10.1002/cbdv.202401309 · Cited by 20
Metadata
- Authors
- Alchin, J., Dhar, A., Siddiqui, K., & Christo, P. J.
- Affiliations
- Burwood Hospital (NZ)
- GlaxoSmithKline Consumer Healthcare Pte Ltd (Singapore) (SG)
- Johns Hopkins University (US)
- Corresponding author
- Dhar, Arti
- ORCID
- Christo, Paul J.
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa UK Limited
- Published
- 2022-03-29
- Volume
- 38
- Issue
- 5
- Pages
- 811-825
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W4220690142
- Cited by
- 65
- References
- 125
- Citations by year
- 2026: 11 · 2025: 15 · 2024: 21 · 2023: 13 · 2022: 5
- FWCI
- 3.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Current Medical Research and Opinion (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- GlaxoSmithKline Consumer Healthcare
- Topics
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Pain Management
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Keywords
- paracetamol, acute pain, analgesic dosing, older adults, liver disease, liver cirrhosis, kidney disease, cardiovascular disease, gastrointestinal diseases, asthma, hepatotoxicity, dose reduction, comorbidities, primary care
- MeSH terms
- Acetaminophen, Adult, Aged, Analgesics, Asthma, Cardiovascular Diseases, Gastrointestinal Diseases, Humans, Kidney, Liver, Analgesics, Non-Narcotic, Acute Pain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Why paracetamol (acetaminophen) is a suitable first choice for treating mild to moderate acute pain in adults with liver, kidney or cardiovascular disease, gastrointestinal disorders, asthma, or who are older. https://app.cochat.ai/papers/10.1080/03007995.2022.2049551
- The paper
- Alchin, J., Dhar, A., Siddiqui, K., & Christo, P. J. (2022). Why paracetamol (acetaminophen) is a suitable first choice for treating mild to moderate acute pain in adults with liver, kidney or cardiovascular disease, gastrointestinal disorders, asthma, or who are older. Current Medical Research and Opinion. https://doi.org/10.1080/03007995.2022.2049551
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.